Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype-Reference-Cited by-同舟云学术

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

Published:2024-09-09 Issue: Volume: Page:
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Jackson David J.¹^ORCID,Wechsler Michael E.¹,Jackson Daniel J.¹,Bernstein David¹,Korn Stephanie¹,Pfeffer Paul E.¹^ORCID,Chen Ruchong¹,Saito Junpei¹,de Luíz Martinez Gustavo¹,Dymek Lucyna¹,Jacques Loretta¹,Bird Nicholas¹,Schalkwijk Stein¹,Smith Douglas¹,Howarth Peter¹,Pavord Ian D.¹

Affiliation:

1. From Guy’s Severe Asthma Centre, Guy’s and St. Thomas’ NHS Foundation Trust, and the School of Immunology and Microbial Sciences, King’s College London (David J. Jackson), Barts Health NHS Trust (P.E.P.), and GSK (L.J., N.B., S.S., P.H.), London, and the Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford (I.D.P.) — all in the United Kingdom; National Jewish Health, Denver (M.E.W.); the University of Wisconsin–Madison, Madison ...

Funder

GlaxoSmithKline

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2406673

Reference31 articles.

1. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era

2. Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. August 2023 (https://ginasthma.org/wp-content/uploads/2023/09/GINA-Severe-Asthma-Guide-2023-WEB-WMS.pdf).

3. Type 2 inflammation in asthma and other airway diseases

4. Comprehensive Characterization of Difficult-to-Treat Asthma Reveals Near Absence of T2-Low Status

5. Interleukin-5 in the Pathophysiology of Severe Asthma